R&D expenses of Innovent Biologics 2019-2023

Published by
Wenyi Zhang,
Nov 18, 2024

In 2023, the Chinese pharmaceutical firm Innovent Biologics Inc. spent more than 2.2 billion yuan on research and development projects, representing a decline of more than 600 million yuan from the previous year. The core products of Innovent Biologics include anti-tumor medicines and drugs treating metabolic disorders and autoimmune diseases.

Research and development spendings of Innovent Biologics Inc. from 2019 to 2023 (in billion yuan)

© Statista 2025
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

March 2024

Region

China

Survey time period

2019 to 2023

Supplementary notes

One yuan equals approximately 0.14 U.S. dollars and 0.13 euros (as of November 2024).

Figures prior to 2022 have been retrieved from the previous publications.
Figures have been rounded for a better understanding.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Jiangsu Hengrui Pharmaceuticals "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Jiangsu Hengrui Pharmaceuticals

Company positioning

6

Key company data

8

Research and development

5

Competitors

5

The oncology drug market

4

Further Content: You might find this interesting as well

Topics

Hengrui PharmaceuticalsMedical technology in ChinaPfizerJohnson & JohnsonPharmaceutical industry in Japan
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.